Gerresheimer AG (GRRMY)
OTCMKTS · Delayed Price · Currency is USD
12.65
0.00 (0.00%)
Aug 8, 2025, 4:00 PM EDT
Satixfy Communications Revenue
Gerresheimer AG had revenue of 600.66M EUR in the quarter ending May 31, 2025, with 19.56% growth. This brings the company's revenue in the last twelve months to 2.19B, up 9.32% year-over-year. In the fiscal year ending November 30, 2024, Gerresheimer AG had annual revenue of 2.04B with 2.28% growth.
Revenue (ttm)
2.19B EUR
Revenue Growth
+9.32%
P/S Ratio
0.74
Revenue / Employee
180.21K EUR
Employees
12,142
Market Cap
1.84B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2024 | 2.04B | 45.42M | 2.28% |
Nov 30, 2023 | 1.99B | 173.39M | 9.54% |
Nov 30, 2022 | 1.82B | 319.09M | 21.30% |
Nov 30, 2021 | 1.50B | 79.22M | 5.58% |
Nov 30, 2020 | 1.42B | 26.53M | 1.91% |
Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |